Metformin improves endotoxemia and alters folliculogenesis in women with polycystic ovary syndrome
Abstract
Polycystic ovary syndrome (PCOS) is associated with excessive ovarian androgen production, increased number of ovarian follicles and a wide range of other endocrine and metabolic derangements including endotoxemia. Metformin is often used in treatment of PCOS, especially to improve glucose metabolism. This study evaluated effects of metformin on endotoxemia, folliculogenesis and endocrine profiles. In a prospective trial, women with PCOS received metformin (500 mg t.i.d.) for three months and underwent baseline and post-treatment evaluations of their endocrine and metabolic profiles as well as detailed ultrasonographic evaluations of ovaries. Metformin treatment was associated with reduced lipopolysaccharides (LPS) by 19% (P<0.0001) and LPS binding protein (LPB) by 26% (P<0.0001). In parallel, the number of small antral follicles (<6mm) declined by 8% (P=0.005), total testosterone decreased by 13% (P=0.0003), ovarian testosterone production in response to hCG declined by 73% (P=0.03) and fasting insulin decreased by 19% (P=0.02). Reduction of testosterone following treatment with metformin may be due to a combination of multiple effects of metformin including improvement of endotoxemia, reduction of folliculogenesis and decreased insulin.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.